EyeCRO scientists contribute to paper published in Biology
Therapeutic Effects of Fenofibrate Nano-Emulsion Eye Drops on Retinal Vascular Leakage and Neovascularization
Similar Posts
Protecting Your Eyes From Macular Degeneration
Macular degeneration, also known as age-related macular degeneration (or AMD) is the most common cause of vision loss in people over age 50, affecting about 10 million Americans. While there’s currently no cure for AMD there are some things you can do if you’re high risk. One option is to talk to your doctor about…
Calcium carbonate templates for drug delivery
The fast and targeted delivery of drugs to the focus of a disease could soon be made easier. Helmuth Möhwald and his colleagues from the Max Planck Institute of Colloids and Interfaces in Golm, Potsdam, have developed a simple technique for the production of drug containers which can be channelled to a selected target in…
Transplanted Rod Precursor Cells Restore Vision in Experimental Mice
Studies in mouse models of night blindness have demonstrated that vision can be restored by transplanting rod precursor cells taken from mouse neonates directly into the retina of recipient animals. The University College London (UCL) Institute of Ophthalmology-led team showed that the transplanted rod cells made synaptic connections with the existing retinal circuitry, were light…
Retinopathy Prevalence Decreasing in Diabetic Adolescents
A 20-year observational study has chronicled notable declines in retinopathy for young patients with type 1 diabetes who receive intensive glycemic control therapy, confirming earlier findings that found a link between normalized blood glucose levels and the slower progression of eye, kidney, and nerve damage. http://www.medscape.com/viewarticle/752133
Gene Therapy Staves Off Blindness from Retinitis Pigmentosa in Canine Model
Gene therapy preserved vision in a study involving dogs with naturally occurring, late-stage retinitis pigmentosa, according to research funded by the National Eye Institute (NEI), part of the National Institutes of Health. The findings contribute to the groundwork needed to move gene therapy forward into clinical trials for people with the blinding eye disorder, for…
Allergan Makes an Eye-Opening Acquisition
Global pharmaceutical company Allergan (NYSE:AGN) may have just revealed its plans for the future. On Aug. 11, the company announced its plan to acquire ForSight Vision5, a privately held biotech. Allergan will pay $95 million up front and will also pay a milestone payment next year if ForSight’s innovative glaucoma treatment device makes it through the…